GPCR/G protein


All GPCRs share a common seven trans-membrane structure. GPCRs are associated with heterotrimeric G-proteins which are GTP-binding proteins made of alpha, beta, and gamma subunits. When a ligand binds to GPCR, it activates the attached G-protein, the GDP is replaced with GTP. The activated G-protein then dissociates into an alpha and a beta-gamma complex which activates downstream signaling pathways. These intracellular signaling pathways include cAMP/PKA, calcium/NFAT, phospholipase C, protein tyrosine kinases, MAP kinases, PI-3-kinase, nitric oxide/cGMP, Rho, and JAK/STAT.
GPCRs are one of the most important therapeutic targets for various diseases, over 30% of all modern medicinal drugs target this family. Aberrant GPCR functions are involved in pathological conditions such as neurological, immunological and hormonal disorders. A large number of GPCRs have been identified, but whose ligands are not known, are classified as orphan receptors.
-
B5425 SHU 9119Summary: melanocortin MC3 and MC4 receptor antagonist -
B5426 [D-Phe12,Leu14]-BombesinSummary: Bombesin receptor antagonist -
B5427 γ1-MSHSummary: melanocortin MC3 receptor agonist -
B5428 JKC 363Summary: melanocortin MC4 receptor antagonist -
B5430 [Ala17]-MCHSummary: melanin-concentrating hormone (MCH) receptor agonist -
B5431 MCL 0020Summary: melanocortin MC4 receptor antagonist -
B5434 ACTH (1-39)Summary: melanocortin receptor 2 (MC2) agonist -
B5446 MMK 1Summary: human formyl peptide receptor FPR2 agonist -
B5450 Parstatin (human)Summary: Cell-permeable peptide that inhibits angiogenesis and exhibits cardioprotective activity -
B5451 Parstatin (mouse)Summary: Cell-permeable peptide that inhibits angiogenesis and exhibits cardioprotective activity

